English
|
Spanish
Supporting oncology professionals through education
Login
Register
The content on this site is intended for healthcare professionals only
Menu
Home
News
Journal
Video
e
learning
Events
Conferences
About us
Keyword
Breast
Prostate & urology
Lung & pleura
Colorectal & gastro
Melanoma & skin
Head & neck
Ovary & gynaecology
Bone
Brain & nervous system
Haematology oncology
Hepatobiliary pancreatic
Paediatric
Neuroendocrine
Sarcomas
News
Latest news
Sign up for news alerts
Submit your news
Explore
Bone
Brain & nervous system
Breast
Colorectal & gastro
Haematology oncology
Head & neck
Hepatobiliary pancreatic
Lung & pleura
Melanoma & skin
Neuroendocrine
Ovary & gynaecology
Paediatric
Prostate & urology
Sarcomas
Journal information
Journal home
Charges
Editorial board
Founding editors
Editor-in-chief
Contact us
Author information
Submit article
Author guidelines
Editorial policies
Copyright information
Why publish with us
Reviewer information
Reviewer guidelines
Memberships
Videos
Recent videos
Sign up
Explore
Bone
Brain & nervous system
Breast
Colorectal & gastro
Haematology oncology
Head & neck
Hepatobiliary pancreatic
Lung & pleura
Melanoma & skin
Neuroendocrine
Ovary & gynaecology
Paediatric
Prostate & urology
Sarcomas
Conferences
Latest conferences
Sign up for latest coverage
Submit your event
About
e
cancer
About
e
cancer
Our founders
Funding statement
Contact us
Home
News
Journal
Video
e
learning
Events
Conferences
About us
Keyword
Breast
Prostate & urology
Lung & pleura
Colorectal & gastro
Melanoma & skin
Head & neck
Ovary & gynaecology
+
-
Bone
Brain & nervous system
Haematology oncology
Hepatobiliary pancreatic
Paediatric
Neuroendocrine
Sarcomas
DNA damage, oncogene activation and chromatin
Share :
ECCO 15 - ESMO 34
20 - 24 Sep 2009
Please rate this video
The information in this video was of interest to me
The information in this video is likely to improve my clinical practice or research
I would recommend this video to my colleagues
Published:
29 Sep 2009
Views:
14259
Rating:
Save
Rate video
Dr Fabrizio d'Adda di Fagagna - Principal Investigator, IFOM-IEO, Milan, Italy
Dr Fabrizio d'Adda di Fagagna, Principal Investigator, IFOM-IEO, Milan, Italy
Categories:
Biology
Cytotoxics
Related Videos
Urinary markers in the surveillance setting of non-muscle invasive bladder...
Dr Thomas Dreyer - Aarhus University Hospital, Aarhus, Denmark
10 Apr 2024
Chemo-immunotherapy combo nivolumab and nab-paclitaxel could be effective...
Dr Chiara Mercinelli - San Raffaele Scientific Institute, Milan, Italy
10 Apr 2024
EAU 2024: Bladder cancer latest
Dr Bernadett Szabados, Dr Félix Guerrero-Ramos, Dr Yohann Loriot, Prof Andrea...
9 Apr 2024
ELCC 2024: Latest in EGFR mutant lung cancer; exon 20 mutation focus
Dr Anna Minchom, Prof Enriqueta Felip, Prof Nicolas Girard and Prof Pascale...
25 Mar 2024
Enfortumab vedotin in combination with pembrolizumab is a potential new...
Dr Michiel Simon Van Der Heijden - Netherlands Cancer Institute, Amsterdam...
30 Jan 2024
What's new on ADCs in management of advanced NSCLC
Dr David Planchard - Institute Gustave Roussy, Villejuif, France
25 Jan 2024
Treatment of metastatic NSCLC without PD-L1 expression and without oncogene...
Dr Antonio Passaro - European Institute of Oncology, Milan, Italy
25 Jan 2024
Nivolumab plus ipilimumab improves on chemo in previously untreated MSI-H/dMMR...
Dr Thierry André - Sorbonne Université, Paris, France
24 Jan 2024
Relapsed Refractory Multiple Myeloma
Dr Hari Menon - St. Johns National Academy of Health Sciences, Bengaluru, India
5 Dec 2023
More from
e
cancer